Literature DB >> 3326667

Mitoxantrone: an active, new antitumor agent with an improved therapeutic index.

S Saletan1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3326667     DOI： 10.1016/0305-7372(87)90021-1

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  4 in total

1.  Prednimustine combined with mitoxantrone and 5-fluorouracil for first and second-line chemotherapy in advanced breast cancer.

Authors:  H Samonigg; H Stöger; A K Kasparek; M Schmid; J Dusleag; K Pfeiffer; M Smola; P Steindorfer; P Lechner
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

2.  Phase I trial of mitoxantrone and granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced solid malignancies.

Authors:  J H Schiller; B Storer; R Arzoomanian; K Tutsch; D Alberti; D Spriggs
Journal:  Invest New Drugs       Date:  1993-11       Impact factor: 3.850

Review 3.  Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection.

Authors:  Marco Bruno Morelli; Chiara Bongiovanni; Silvia Da Pra; Carmen Miano; Francesca Sacchi; Mattia Lauriola; Gabriele D'Uva
Journal:  Front Cardiovasc Med       Date:  2022-04-15

Review 4.  Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic Drugs.

Authors:  Marilisa Molinaro; Pietro Ameri; Giancarlo Marone; Mario Petretta; Pasquale Abete; Fabio Di Lisa; Sabino De Placido; Domenico Bonaduce; Carlo G Tocchetti
Journal:  Biomed Res Int       Date:  2015-10-25       Impact factor: 3.411
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.